[go: up one dir, main page]

BR0316111A - Métodos para diagnosticar rcc e outros tumores sólidos - Google Patents

Métodos para diagnosticar rcc e outros tumores sólidos

Info

Publication number
BR0316111A
BR0316111A BR0316111A BR0316111A BR0316111A BR 0316111 A BR0316111 A BR 0316111A BR 0316111 A BR0316111 A BR 0316111A BR 0316111 A BR0316111 A BR 0316111A BR 0316111 A BR0316111 A BR 0316111A
Authority
BR
Brazil
Prior art keywords
solid tumors
methods
rcc
ccr
genes
Prior art date
Application number
BR0316111A
Other languages
English (en)
Inventor
Natalie Constance Twine
Michael E Burczynski
William L Trepicchio
Andrew Dorner
Jennifer A Stover
Donna K Slonim
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0316111A publication Critical patent/BR0316111A/pt

Links

Classifications

    • G01N33/57525—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODOS PARA DIAGNOSTICAR RCC E OUTROS TUMORES SóLIDOS". Métodos, sistemas e equipamentos para diagnosticar o carcinoma de células renais (RCC) e outros tumores sólidos. Esta invenção identifica numerosos genes doentios que são diferencialmente expressos no sangue periférico de pacientes tendo RCC ou outros tumores sólidos em relação aos seres humanos livres de doença. Estes genes doentios podem ser usados como marcadores substitutos para detectar a presença ou ausência de RCC ou outros tumores sólidos.
BR0316111A 2002-11-21 2003-11-21 Métodos para diagnosticar rcc e outros tumores sólidos BR0316111A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42798202P 2002-11-21 2002-11-21
US45978203P 2003-04-03 2003-04-03
PCT/US2003/037481 WO2004048933A2 (en) 2002-11-21 2003-11-21 Methods for diagnosing rcc and other solid tumors

Publications (1)

Publication Number Publication Date
BR0316111A true BR0316111A (pt) 2005-09-13

Family

ID=32397089

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316111A BR0316111A (pt) 2002-11-21 2003-11-21 Métodos para diagnosticar rcc e outros tumores sólidos

Country Status (8)

Country Link
US (1) US7611839B2 (pt)
EP (1) EP1588142A4 (pt)
JP (1) JP2006514554A (pt)
AU (1) AU2003298689A1 (pt)
BR (1) BR0316111A (pt)
CA (1) CA2505416A1 (pt)
MX (1) MXPA05005283A (pt)
WO (1) WO2004048933A2 (pt)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248170A1 (en) * 1999-01-06 2004-12-09 Chondrogene Limited Method for the detection of hyperlipidemia related gene transcripts in blood
US20090215024A1 (en) * 2001-01-24 2009-08-27 Health Discovery Corporation Biomarkers upregulated in prostate cancer
US20090226915A1 (en) 2001-01-24 2009-09-10 Health Discovery Corporation Methods for Screening, Predicting and Monitoring Prostate Cancer
US20090215058A1 (en) * 2001-01-24 2009-08-27 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
US8008012B2 (en) * 2002-01-24 2011-08-30 Health Discovery Corporation Biomarkers downregulated in prostate cancer
WO2003099312A1 (en) 2002-05-27 2003-12-04 Östergötlands Läns Landsting Method for determining immune system affecting compounds
US8163692B2 (en) * 2002-11-13 2012-04-24 University Of North Texas Health Science Center Of Fort Worth Protection against and treatment of ionizing radiation
US9895413B2 (en) 2002-11-13 2018-02-20 Board Of Regents, University Of Texas System Protection against and treatment of ionizing radiation
US20050123594A1 (en) * 2002-11-13 2005-06-09 Sanjay Awasthi Liposomes for protection against toxic compounds
US20060182749A1 (en) * 2002-11-13 2006-08-17 Board Of Regents, The University Of Texas System Therapies for cancer using RLIP76
JP2006514554A (ja) 2002-11-21 2006-05-11 ワイス 腎細胞癌および他の固形腫瘍の診断法
CA2514058C (en) 2003-01-24 2014-05-13 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
US7643943B2 (en) 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
CA2515677A1 (en) * 2003-02-11 2004-08-26 Wyeth Methods for monitoring drug activities in vivo
US20050287532A9 (en) * 2003-02-11 2005-12-29 Burczynski Michael E Methods for monitoring drug activities in vivo
EP1618218A2 (en) * 2003-04-29 2006-01-25 Wyeth Methods for prognosis and treatment of solid tumors
EP1522857A1 (en) 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
WO2005075414A1 (ja) * 2004-02-04 2005-08-18 Yokohama City University ぺプチジルアルギニンデイミナーゼ４阻害剤
WO2006002240A2 (en) * 2004-06-19 2006-01-05 Chondrogene, Inc. Computer systems and methods for constructing biological classifiers and uses thereof
US7991557B2 (en) * 2004-06-19 2011-08-02 Genenews Corporation Computer system and methods for constructing biological classifiers and uses thereof
US8080373B2 (en) * 2004-08-03 2011-12-20 Bauer Jr A Robert Method for the early detection of pancreatic cancer and other gastrointestinal disease conditions
US20080280282A1 (en) * 2004-08-03 2008-11-13 Bauer Jr A Robert Method for early detection of various cancers and gastrointestinal disease and monitoring of transplanted organs
US7820382B2 (en) * 2004-08-03 2010-10-26 Bauer A Robert Method for the early detection of breast cancer, lung cancer, pancreatic cancer and colon polyps, growths and cancers as well as other gastrointestinal disease conditions and the preoperative and postoperative monitoring of transplanted organs from the donor and in the recipient and their associated conditions related and unrelated to the organ transplantation
US20060094018A1 (en) * 2004-08-03 2006-05-04 Bauer A R Jr Discovery and a method for the early detection of pancreatic cancer and other disease conditions
SE0402536D0 (sv) 2004-10-20 2004-10-20 Therim Diagnostica Ab Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
US11105808B2 (en) 2004-11-12 2021-08-31 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
CA2596469A1 (en) * 2005-02-01 2006-08-10 Government Of The U.S.A, As Represented By The Secretary Department Of H Ealth & Human Services Biomarkers for tissue status
WO2006097388A2 (en) * 2005-02-08 2006-09-21 Innogenetics N.V. Nucleic acid variants in the c1qr1 gene associated with altered innate immunity.
WO2006089185A2 (en) * 2005-02-18 2006-08-24 Wyeth Pharmacogenomic markers for prognosis of solid tumors
EP1875246B1 (en) 2005-04-15 2016-10-05 CanImGuide Therapeutics AB Diagnostic method for detecting cancer by measuring amount of a cytokine like il-6
EP2395101B1 (en) * 2005-05-02 2013-11-13 University of Southern California DNA methylation markers associated with the CpG island methylator phenotype (cimp) in human colorectal cancer
WO2007026896A1 (ja) 2005-09-02 2007-03-08 Toray Industries, Inc. 腎ガン診断、腎ガン患者予後予測のための組成物および方法
JPWO2007099852A1 (ja) * 2006-02-23 2009-07-16 国立大学法人金沢大学 固形癌のチロシンキナーゼ阻害剤に対する感受性を検査する方法及び検査キット
WO2008086502A2 (en) * 2007-01-10 2008-07-17 University Of Chicago Molecular marker for clear renal cell carcinoma
DK2487186T3 (da) 2007-05-08 2017-01-16 Canimguide Therapeutics Ab Immunregulatoriske strukturer fra normalt forekommende proteiner
KR20110000548A (ko) 2008-01-17 2011-01-03 도레이 카부시키가이샤 신장암의 진단 또는 검출을 위한 조성물 및 방법
CN107254517A (zh) * 2008-01-18 2017-10-17 哈佛大学校长及研究员协会 在体液中检测疾病或病症标志的方法
CN101980724A (zh) 2008-02-07 2011-02-23 泰拉皮奥公司 递送货物诸如药物蛋白和/或遗传物质的组合物
GB0803464D0 (en) * 2008-02-26 2008-04-02 Medical Res Council Methods and compositions
DE102008031699A1 (de) * 2008-07-04 2010-01-14 Protagen Ag Markersequenzen für Prostataentzündungserkrankungen, Prostatakarzinom und deren Verwendung
EP2329040B1 (en) * 2008-09-22 2017-10-11 ADVPharma, Inc. Molecular markers for lung and colorectal carcinomas
CN102246038B (zh) * 2008-10-21 2014-06-18 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
AU2009340423B2 (en) * 2008-10-29 2014-07-24 Bg Medicine, Inc. Galectin-3 immunoassay
KR101087617B1 (ko) * 2009-03-19 2011-11-29 한국생명공학연구원 Ｅｎｉｇｍａ―Ｍｄｍ２ 상호작용 및 그 용도
CN102573874A (zh) * 2009-07-24 2012-07-11 泰拉皮奥公司 用于辐射后保护的组合物和方法
JP5702386B2 (ja) * 2009-08-25 2015-04-15 ビージー メディシン， インコーポレイテッド ガレクチン−３および心臓再同期療法
WO2011073905A1 (en) * 2009-12-14 2011-06-23 Koninklijke Philips Electronics N.V. Novel tumor markers
DK3178944T3 (da) 2010-01-11 2019-08-12 Genomic Health Inc Fremgangsmåde til anvendelse af genekspression til bestemmelse af sandsynligheden for et klinisk resultat for nyrecancer
JP2013533960A (ja) 2010-06-01 2013-08-29 トドス メディカル リミテッド がんの診断
US20110301110A1 (en) * 2010-06-03 2011-12-08 Aucagne Romain TRIM33 (TIF1gamma) AS A NEW DIAGNOSTIC MARKER OF CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
EP2707710B1 (en) 2011-05-11 2022-08-17 Todos Medical Ltd. Diagnosis of cancer based on infrared spectroscopic analysis of dried blood plasma samples
JP5872285B2 (ja) * 2011-12-28 2016-03-01 株式会社島津製作所 腎がん血中マーカー
AU2013203713B2 (en) 2012-02-13 2015-07-16 Terapio Corporation RLIP76 as a medical chemical countermeasure
US9493810B2 (en) 2012-06-07 2016-11-15 Pioma, Inc. 5-ALA for detection of brain tumors
US20140005058A1 (en) * 2012-06-28 2014-01-02 Caldera Health Ltd. Methods and materials for the diagnosis of prostate cancers
MX365158B (es) 2012-10-31 2019-05-24 Ionis Pharmaceuticals Inc Compuestos antisentido para usarse en el tratamiento de linfoma de células b.
US20160222457A1 (en) * 2012-11-14 2016-08-04 Mayo Foundation For Medical Education And Research Methods and materials for identifying malignant skin lesions
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
WO2014164366A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting cancer
WO2014164365A1 (en) * 2013-03-09 2014-10-09 Harry Stylli Methods of detecting head and neck cancer
US9804145B2 (en) 2013-05-28 2017-10-31 Todos Medical Ltd. Infrared analysis of benign tumors
CA2903878C (en) 2013-05-30 2020-10-27 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
EP3046544A4 (en) 2013-09-17 2017-03-22 Terapio Corporation Methods of preventing or treating mucositis using rlip76
US9611304B2 (en) * 2014-05-29 2017-04-04 The University Of British Columbia TNNT1 mini-promoters
WO2016025717A1 (en) 2014-08-14 2016-02-18 Mayo Foundation For Medical Education And Research Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer
EP3550306B1 (en) 2014-08-26 2021-03-03 Keio University Anti-cancer agent sensitivity-determining marker
WO2016040843A1 (en) 2014-09-11 2016-03-17 Harry Stylli Methods of detecting prostate cancer
EP3067698A1 (en) 2015-03-11 2016-09-14 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Pd-ecgf as biomarker of cancer
WO2017132169A1 (en) * 2016-01-28 2017-08-03 Siemens Healthcare Diagnostics Inc. Methods and apparatus for detecting an interferent in a specimen
EP3408641B1 (en) * 2016-01-28 2021-05-26 Siemens Healthcare Diagnostics Inc. Methods and apparatus for multi-view characterization
AU2017261688B2 (en) 2016-05-10 2022-09-29 Mayo Foundation For Medical Education And Research Methods and materials for staging and treating skin cancer
US20200123608A1 (en) * 2016-10-05 2020-04-23 Institute Of Environmental Science And Research Limited Rna sequences for body fluid identification
WO2019027693A1 (en) * 2017-07-31 2019-02-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education AUTOMATIC AND EARLY DETECTION SYSTEM FOR FREE SHUTTLE
KR20210044233A (ko) 2018-07-25 2021-04-22 스카이라인덱스 비.브이. 흑색종의 전이 및 환자의 예후를 예측하기 위한 유전자 서명
WO2020081956A1 (en) 2018-10-18 2020-04-23 Medimmune, Llc Methods for determining treatment for cancer patients
WO2021030604A1 (en) * 2019-08-14 2021-02-18 University Of Massachusetts Urinary rna signatures in renal cell carcinoma (rcc)
CN113025716A (zh) * 2021-03-02 2021-06-25 北京大学第一医院 一种用于人肿瘤分级的基因组合及其用途
US20250018061A1 (en) * 2021-12-02 2025-01-16 The Children`S Medical Center Corporation Gene therapy in succinic semialdehyde dehydrogenase deficiency (ssadhd)
WO2024192027A1 (en) * 2023-03-12 2024-09-19 Novelna Inc. Kidney cancer detection proteins and methods of use thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
WO1983001451A1 (en) * 1981-10-23 1983-04-28 Molecular Biosystems Inc Oligonucleotide therapeutic agent and methods of making same
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4625014A (en) * 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) * 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5459039A (en) * 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5498531A (en) * 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5840506A (en) * 1996-06-05 1998-11-24 Thomas Jefferson University Methods for the diagnosis and prognosis of cancer
US5919638A (en) * 1996-10-08 1999-07-06 Abbott Laboratories Reagents and methods useful for detecting prostate tumors
US6303301B1 (en) * 1997-01-13 2001-10-16 Affymetrix, Inc. Expression monitoring for gene function identification
US6063028A (en) * 1997-03-20 2000-05-16 Luciano; Joanne Sylvia Automated treatment selection method
US6190857B1 (en) * 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
US6087098A (en) * 1997-04-15 2000-07-11 The Trustees Of Columbia University In The City Of New York Enhanced reverse transcriptase polymerase chain assay to detect MN in patients with renal cell carcinoma
US6420108B2 (en) * 1998-02-09 2002-07-16 Affymetrix, Inc. Computer-aided display for comparative gene expression
AU9319398A (en) 1997-09-19 1999-04-05 Sequitur, Inc. Sense mrna therapy
US20030104371A1 (en) 1997-09-24 2003-06-05 Strom Terry B. Methods of evaluating transplant rejection
FR2771422B1 (fr) 1997-11-21 2001-07-27 Centre Nat Rech Scient Reactifs et methodes pour la detection de genes lies au complexe majeur d'histocompatibilite d'oiseaux d'elevage, tels que le poulet
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
JP3944996B2 (ja) * 1998-03-05 2007-07-18 株式会社日立製作所 Ｄｎａプローブアレー
CA2359816C (en) 1999-01-06 2010-08-03 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6605273B2 (en) * 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6647341B1 (en) * 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
CN1375004A (zh) 1999-04-21 2002-10-16 惠氏公司 抑制多核苷酸序列的功能的方法和组合物
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20020168638A1 (en) * 2000-01-24 2002-11-14 Robert Schlegel Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
JP2003526367A (ja) 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Ｒｎａ干渉の方法とｒｎａ干渉組成物
CA2403162A1 (en) 2000-03-17 2001-09-27 Benitec Australia Ltd. Genetic silencing
NZ522045A (en) 2000-03-30 2007-05-31 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
US20100305186A1 (en) 2000-05-30 2010-12-02 Johnson & Johnson Research Pty Limited Methods for mediating gene suppression
US20020042072A1 (en) * 2000-06-26 2002-04-11 Jacobus Van Meel Method for monitoring the effect of cancer therapies
AU2001277959A1 (en) 2000-07-21 2002-02-05 Incyte Genomics, Inc. Human kinases
JP2004525609A (ja) 2000-09-21 2004-08-26 インサイト・ゲノミックス・インコーポレイテッド プロテインホスファターゼ
US7198895B2 (en) * 2000-11-14 2007-04-03 Mohanlal Ramon W In vitro cell-based methods for biological validation and pharmacological screening of chemical entities and biologicals
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
DE10057894A1 (de) * 2000-11-22 2002-06-06 Adnagen Gmbh Diagnose-Kit, DNS-Chip sowie Verfahren zur Diagnostik oder Behandlungskontrolle bei Hodenkrebs
IL155953A0 (en) * 2000-11-28 2003-12-23 Wyeth Corp Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US20020164664A1 (en) * 2000-11-30 2002-11-07 Matritech, Inc. Detection and treatment of prostate cancer
US20020132274A1 (en) * 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
EP1442062A4 (en) 2001-10-18 2005-11-09 Genentech Inc METHOD FOR TREATING CARCINOMA
JP2006514554A (ja) 2002-11-21 2006-05-11 ワイス 腎細胞癌および他の固形腫瘍の診断法
US7643943B2 (en) * 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
US20050287532A9 (en) * 2003-02-11 2005-12-29 Burczynski Michael E Methods for monitoring drug activities in vivo
CA2515677A1 (en) 2003-02-11 2004-08-26 Wyeth Methods for monitoring drug activities in vivo
EP1618218A2 (en) 2003-04-29 2006-01-25 Wyeth Methods for prognosis and treatment of solid tumors

Also Published As

Publication number Publication date
EP1588142A4 (en) 2007-10-31
EP1588142A2 (en) 2005-10-26
US7611839B2 (en) 2009-11-03
CA2505416A1 (en) 2004-06-10
AU2003298689A1 (en) 2004-06-18
WO2004048933A2 (en) 2004-06-10
WO2004048933A3 (en) 2005-11-10
US20040110221A1 (en) 2004-06-10
JP2006514554A (ja) 2006-05-11
MXPA05005283A (es) 2005-07-25

Similar Documents

Publication Publication Date Title
BR0316111A (pt) Métodos para diagnosticar rcc e outros tumores sólidos
WO2006089233A3 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
EP1578923A4 (en) SOLUBLE MIC POLYPEPTIDE AS A MARKER FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER AND AUTOIMMUNE DISEASES OR DISEASES
EP1363920A4 (en) MODIFIED PSMA LIGANDS AND THEIR USE
DE60237531D1 (de) Verfahren zum trennen von seltenen zellen von fluidproben
DE60016467D1 (de) Ct-systeme zur klinischen überprüfung
DE69930666D1 (de) Krebsnachweisverfahren und reagenzien
WO2004066808A3 (en) Glycan markers for diagnosing and monitoring disease
WO2006093507A3 (en) Methods and systems for predicting cancer outcome
ATE394658T1 (de) Spurendetektion von analyten mit hilfe artifizieller olfaktometrie
DE69933661D1 (de) Genomische sequenz des 5-lipoxygenase-aktivierenden proteins (flap), polymorphische marker und ihre anwendung in der diagnose von asthma
EP2924440A3 (en) Markers associated with arteriovascular events and methods of use thereof
ATE440629T1 (de) Kanüleneinführungssystem
DE602004028513D1 (de) Verfahren zum nachweis von mit endometrialer krankheit oder phase assoziierten markern
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
NO20072296L (no) Fremgangsmater og systemer for prognose og behandling av faste tumorer
BRPI0214840B8 (pt) métodos para a detecção de mutações oncogênicas humanas, métodos automatizados para detectar uma mutação e método e ensaio para identificar um ou mais compostos tendo atividade anti-proliferativa
NL1020758A1 (nl) Werkwijze voor computertomografie alsmede computertomografie(CT-)apparaat.
BR0317394A (pt) Uso de nicotinamida n-metiltransferase como um marcador para câncer colorretal
WO2002059822A3 (en) Methods of identifying patterns in biological systems and uses thereof
DE10292329D2 (de) Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
ATE426169T1 (de) Fruher nachweis einer lysosomalen speicher- krankheit
WO2005085860A3 (en) New proliferation markers in clinical practice and their use for cancer prognosis or diagnosis
DE60003289D1 (de) Kombinationstherapie für lymphoproliferative krankheiten
FR2795823B1 (fr) Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]